114.22
1.59 (1.41%)
| Previous Close | 112.63 |
| Open | 112.54 |
| Volume | 851,343 |
| Avg. Volume (3M) | 729,443 |
| Market Cap | 5,521,015,296 |
| Price / Book | 54.29 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2026 |
| Diluted EPS (TTM) | -3.05 |
| Total Debt/Equity (MRQ) | 113.89% |
| Current Ratio (MRQ) | 6.61 |
| Operating Cash Flow (TTM) | -102.25 M |
| Levered Free Cash Flow (TTM) | -62.83 M |
| Return on Assets (TTM) | -39.04% |
| Return on Equity (TTM) | -115.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Celcuity Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.21% |
| % Held by Institutions | 81.78% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nea Management Company, Llc | 31 Dec 2025 | 3,535,561 |
| Perceptive Advisors Llc | 31 Dec 2025 | 3,160,200 |
| Avoro Capital Advisors Llc | 31 Dec 2025 | 3,111,111 |
| Soleus Capital Management, L.P. | 31 Dec 2025 | 1,808,258 |
| Deerfield Management Company, L.P. | 31 Dec 2025 | 1,714,000 |
| Tang Capital Management Llc | 31 Dec 2025 | 1,050,000 |
| Holocene Advisors, Lp | 31 Dec 2025 | 695,340 |
| 52 Weeks Range | ||
| Median | 122.00 (6.81%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 10 Mar 2026 | 122.00 (6.81%) | Buy | 117.10 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BULLER RICHARD E | - | 114.14 | -3,000 | -342,420 |
| Aggregate Net Quantity | -3,000 | |||
| Aggregate Net Value ($) | -342,420 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 114.14 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BULLER RICHARD E | Director | 31 Mar 2026 | Automatic sell (-) | 3,000 | 114.14 | 342,420 |
| BULLER RICHARD E | Director | 31 Mar 2026 | Option execute | 3,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 20 Jan 2026 | Announcement | Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |